PCM
HALO icon

Piermont Capital Management’s Halozyme HALO Stock Holding History

Piermont Capital Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-22,500
Closed -$380K – 149
2018
Q2 		$380K Buy
22,500
+12,000
+114% +$227K 0.12% 186
2018
Q1 		$206K Buy
+10,500
New +$203K 0.07% 231

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Piermont Capital Management's HALO Position: Q3 2018 in Review

Piermont Capital Management sold out of Halozyme (HALO) in Q3 2018, closing a stake of 22,500 shares — an estimated $380K sold.

Piermont Capital Management first reported a position in HALO in Q1 2018 and held it in 2 quarters. The position peaked at $380K in Q2 2018. 193 funds tracked by Wall St. Rank hold HALO as of Q3 2018.

  • Piermont Capital Management reported no remaining Halozyme position as of Q3 2018 after selling out during the quarter.
  • Piermont Capital Management sold 22,500 Halozyme shares in Q3 2018, an estimated $380K.
  • Piermont Capital Management first reported a position in Halozyme in Q1 2018 and held it in 2 quarters.
  • Piermont Capital Management's Halozyme position peaked at $380K in Q2 2018.
  • 193 funds tracked by Wall St. Rank held Halozyme as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.